HSP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Hospira Inc's research and development for the three months ended in Mar. 2015 was $135 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2015 was $397 Mil.
This is the expense the company spent on research and development.
Hospira Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2015 was 75.7 (Jun. 2014 ) + 86.3 (Sep. 2014 ) + 99.1 (Dec. 2014 ) + 135.4 (Mar. 2015 ) = $397 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Hospira Inc Annual Data
|Research & Development||139||162||201||214||241||301||259||304||302||344|
Hospira Inc Quarterly Data
|Research & Development||85||74||74||70||84||83||76||86||99||135|